SEC FIlings Archives - Page 9 of 19

15 Nov

SEC FIlings

Statement of changes in beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Statement of changes in beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Statement of changes in beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Statement of changes in beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

SEC FIlings

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists